STOCK TITAN
  1. Home
  2. News
  3. APDN

Applied DNA Sciences, Inc. - APDN STOCK NEWS

Welcome to our dedicated page for Applied DNA Sciences news (Ticker: APDN), a resource for investors and traders seeking the latest updates and insights on Applied DNA Sciences stock.

Applied DNA Sciences, Inc. (NASDAQ: APDN) is a biotechnology company pioneering advanced DNA-based technologies to safeguard assets and enhance industrial and healthcare applications. Headquartered in Stony Brook, NY, Applied DNA leverages Polymerase Chain Reaction (PCR) to produce and detect DNA and RNA, operating in three key segments: Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services.

In the Therapeutic DNA Production Services segment, Applied DNA produces synthetic DNA for nucleic acid-based therapeutics. With the acquisition of Spindle Biotech, the company has expanded its portfolio to include a proprietary RNA polymerase (RNAP) for mRNA therapeutics manufacturing. The recent contract with HDT Bio under the 'Project NextGen: Enabler' award aims to expedite mRNA vaccine production, highlighting the company's commitment to rapid-response medical solutions.

The MDx Testing Services segment, which includes clinical molecular diagnostic and genetic testing services, significantly contributes to the company's revenue. Applied DNA's innovative Linea™ IVT platform, designed to produce high-fidelity mRNA with reduced contamination, is a game-changer in molecular diagnostics.

Through the DNA Tagging and Security Products and Services segment, the company offers solutions under the brands Applied DNA Sciences, SigNature®, SigNature® T, fiberTyping, and SigNify®, providing robust anti-counterfeiting and product authentication services. These services are essential for supply chain security across various industries, including textiles and pharmaceuticals.

Recent achievements include closing a $12 million public offering to fund the development of DNA production services and the successful reverse stock split to comply with Nasdaq's minimum bid price requirements. Additionally, Applied DNA received a Notice of Allowance from the USPTO for a patent on its Linea™ RNAP, solidifying its intellectual property portfolio and extending patent protection into 2041.

Applied DNA remains dedicated to advancing DNA technology to meet the world’s evolving needs in healthcare, supply chain security, and beyond. For more information, visit their website at www.adnas.com and follow them on social media for the latest updates.

News

Applied DNA Announces First Quarter Fiscal Year 2024 Financial Results

Rhea-AI Summary
Applied DNA Sciences, Inc. (APDN) announced first-quarter fiscal 2024 financial results. The company is on track to initiate first-phase GMP production capacity for mRNA critical starting materials during the first half of calendar 2024. The initial facility capacity is projected to enable up to $15 million of Linea IVT revenue annually. The company also announced the completion of an equity offering to support the initial phase of the GMP plan and timeline for critical starting materials in the production of mRNA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.67%
Tags
earnings
-
News

Applied DNA to Report First Quarter Fiscal 2024 Financial Results on Thursday, February 8, 2024

Rhea-AI Summary
Applied DNA Sciences, Inc. (NASDAQ:APDN) will release its first quarter fiscal 2024 financial results on February 8, 2024, after market close. A conference call for analysts and investors will be held the same day at 4:30 p.m. ET to discuss the financial results and recent accomplishments. The call will be accessible via dial-in and live webcast, with a replay available for 7 days. An accompanying slide presentation will be available on the company's investor relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
conferences earnings
-
News

Applied DNA Announces Closing of $3.44 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Rhea-AI Summary
Applied DNA Sciences, Inc. (APDN) has closed a direct offering of common stock and issued unregistered warrants to certain institutional investors. The company also amended the exercise price and expiration dates of previously issued common stock warrants. The net proceeds from the offering will be used for therapeutic DNA production services and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
offering
News

Applied DNA Announces $3.44 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Rhea-AI Summary
Applied DNA Sciences, Inc. (APDN) has entered into securities purchase agreements with existing institutional investors for the issuance and sale of 5,644,061 shares of common stock at a purchase price of $0.609 per share in a registered direct offering. In a concurrent private placement, the company has also agreed to issue and sell unregistered warrants to purchase up to 11,288,122 shares of its common stock. The warrants have an exercise price of $0.609 per share and will become exercisable on the first trading day after receipt of shareholder approval. Additionally, the company will reduce the exercise price of 3,055,139 common stock warrants previously issued to the investors and extend warrant expiration dates into 2028, subject to approval by the company's stockholders at a stockholder meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.33%
Tags
offering
-
News

Applied DNA Announces Joint Development Agreement to Integrate Linea(TM) IVT Platform into CDMO Kudo Biotechnology’s mRNA Manufacturing Workflow

Rhea-AI Summary
Applied DNA Sciences, Inc. (NASDAQ:APDN) and Kudo Biotechnology (Kudo Bio) have entered into a joint development agreement to integrate Applied DNA's Linea IVT platform into Kudo Bio's commercial mRNA manufacturing workflows. The agreement aims to optimize mRNA quality, yields, and mitigate contamination by double-stranded RNA (dsRNA) at manufacturing scale. Upon successful completion, the joint workflow is planned for commercial launch in the second half of calendar 2024. The Linea IVT Platform is expected to provide advantages over conventional mRNA manufacturing methods, including the prevention or reduction of dsRNA contamination and reduced mRNA manufacturing turn-around-times.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.89%
Tags
none
-
News

Applied DNA Announces Fourth Quarter Fiscal Year 2023 Financial Results

Rhea-AI Summary
Applied DNA Sciences, Inc. (NASDAQ:APDN) announced consolidated financial results for its fourth quarter ended September 30, 2023. The company's total revenues were approximately $780 thousand, a decrease from $3.6 million for the same period in the prior fiscal year. Operating loss decreased to $4.2 million for the three-month period ended September 30, 2023, as compared to $4.3 million for the fourth quarter of fiscal 2022. Net loss was $3.6 million for the three-month period ended September 30, 2023, compared to $665 thousand for the fourth quarter of 2022. Cash and cash equivalents stood at $7.2 million on September 30, 2023, compared with $10.8 million as of June 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.52%
Tags
earnings
News

Applied DNA to Report Fiscal 2023 Fourth Quarter and Year End Financial Results on December 7, 2023

Rhea-AI Summary
Applied DNA Sciences, Inc. (NASDAQ:APDN) will release its Q4 and full year 2023 financial results on December 7, 2023, after the market close. The company will host a conference call to discuss the results and answer questions at 4:30 p.m. ET. Details for accessing the call and webcast are provided in the press release.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.04%
Tags
conferences earnings
-
News

Applied DNA Announces Receipt of Linea(TM) DNA Follow-On Order for Cancer Diagnostic Application

Rhea-AI Summary
Applied DNA Sciences, Inc. (APDN) announced a follow-on order for Linea DNA valued above the mid-six figures for a global manufacturer of in vitro diagnostics. Deliveries are expected to commence from March 31, 2024, through December 31, 2024. Dr. James A. Hayward, president and CEO, highlighted the strong demand for IVD-related applications for Linea DNA, emphasizing the potential for high-margin recurring revenues and incremental revenues through new customer acquisition and expanded use by existing customers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.27%
Tags
none
-
News

Applied DNA Extends Application of Linea(TM) IVT Platform to saRNA (self-amplifying mRNA)

Rhea-AI Summary
Applied DNA Sciences, Inc. (NASDAQ:APDN) announced the expansion of its Linea™ IVT platform to include the manufacture of self-amplifying mRNA (saRNA). The Platform was previously optimized for conventional non-amplifying mRNA constructs and has now been extended to enable the production of saRNA, a promising new form of mRNA therapy engineered to possess self-replicating capability. This expansion increases the Company's total addressable market and is the result of ongoing platform development and optimization. The Company believes that the Platform provides numerous advantages over conventional mRNA manufacturing methods, including higher target mRNA yields, faster delivery of IVT templates, and reduced manufacturing complexities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5%
Tags
none
News

Applied DNA Ships First saRNA (self-amplifying mRNA) IVT Template Generated by Linea(TM) DNA Platform

Rhea-AI Summary
Applied DNA Sciences, Inc. (NASDAQ:APDN) announced the successful manufacturing and shipment of self-amplifying mRNA (saRNA) template using its Linea™ DNA platform to an unidentified preclinical therapeutic mRNA developer. This saRNA technology is gaining interest due to its self-replicating capability, resulting in a higher therapeutic index at a lower dose. The Company's Platform can efficiently produce the challenging DNA sequences necessary to manufacture saRNA at scale, positioning it at the forefront of template manufacturing for this promising mRNA modality.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.26%
Tags
none

FAQ

What is the current stock price of Applied DNA Sciences (APDN)?

The current stock price of Applied DNA Sciences (APDN) is $0.1791 as of December 24, 2024.

What is the market cap of Applied DNA Sciences (APDN)?

The market cap of Applied DNA Sciences (APDN) is approximately 9.4M.

What services does Applied DNA Sciences provide?

Applied DNA Sciences offers Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services.

What is the Linea™ IVT platform?

The Linea™ IVT platform produces high-fidelity mRNA with reduced contamination, streamlining mRNA production workflows.

How does Applied DNA contribute to supply chain security?

Applied DNA provides DNA tagging and authentication solutions under brands like SigNature® and SigNify® to protect products and brands from counterfeiting and fraud.

What was the purpose of the recent public offering by Applied DNA?

The $12 million public offering aims to further develop Therapeutic DNA Production Services and MDx Testing Services, alongside general corporate purposes.

What recent patent has Applied DNA received?

Applied DNA received a Notice of Allowance from the USPTO for a patent on its Linea™ RNAP, which will extend protection into 2041.

What is the significance of the reverse stock split?

The 1-for-20 reverse stock split ensures compliance with Nasdaq's minimum bid price requirements, maintaining the company’s listing on the exchange.

Which markets does Applied DNA Sciences primarily serve?

Applied DNA serves markets in synthetic DNA manufacturing for therapeutics, molecular diagnostics, genetic testing, and industrial supply chain security.

How does Applied DNA's technology benefit mRNA vaccine production?

Applied DNA's Linea™ IVT platform enables rapid, scalable production of high-quality mRNA, crucial for fast-response vaccine manufacturing.

What recent collaborations has Applied DNA announced?

Applied DNA announced a collaboration with HDT Bio under 'Project NextGen: Enabler' for rapid mRNA vaccine production and with Alphazyme for scaling RNAP manufacturing.

Where can investors find more information about Applied DNA?

Investors can visit Applied DNA's official website at www.adnas.com and check their latest filings on the SEC's website for detailed financial and strategic information.

Stock APDN logo
Applied DNA Sciences, Inc.

Nasdaq:APDN

APDN Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

APDN Stock Data

9.37M
41.55M
0.62%
0.5%
0.94%
Diagnostics & Research
Services-testing Laboratories
Link
United States of America
STONY BROOK